Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease

BACKGROUND: Erdheim‐Chester disease (ECD) is a rare non‐Langerhans cell histiocytosis. The BRAF inhibitor vemurafenib is approved by the U.S. Food and Drug Administration (FDA) for patients with ECD harboring a BRAF V600E mutation. Successful treatment has also been reported with MEK‐targeted therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, Ila M., Goodman, Aaron M., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011668/
https://www.ncbi.nlm.nih.gov/pubmed/32043767
http://dx.doi.org/10.1634/theoncologist.2019-0606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011668/
https://www.ncbi.nlm.nih.gov/pubmed/32043767
http://dx.doi.org/10.1634/theoncologist.2019-0606

Ejemplares similares